A股公司为何争相奔赴港股市场？深圳市双玺科创产业发展有限公司总经理高中青对记者表示："主要 是为企业出海筹集资金，同时方便海外布局。" （上接1版） 科技公司领军"南下" 2026年开年这一波冲刺H股的A股公司，大多为科技企业。例如：聚辰股份是一家全球化的芯片设计高 新技术企业；景旺电子是全球领先的印制电路板及高端电子材料企业；鹏辉能源以科技创新驱动发展， 聚焦于电池产品及储能系统领域；德赛西威则是国际领先的移动出行科技公司之一，致力于实现智慧出 行的全球共享。 生物医药行业A股公司赴港上市意愿也颇为强烈。益方生物聚焦于肿瘤、自身免疫性疾病及代谢类疾病 等重大疾病领域，所有产品均为自主研发。资料显示，公司已成功推动两款创新药获批上市，并有三个 候选药物处于临床试验阶段。 毕马威中国香港资本市场组主管合伙人刘大昌认为，越来越多高科技及生物科技企业选择来港上市，随 着政策持续推动创新及新经济领域的发展，2026年将是高科技上市的关键一年。 实际上，2026年开年"南下"潮是2025年"A+H"上市热度的延续。据德勤中国资本市场服务部发布的报 告，2025年港股活跃上市申请个案较2024年全年的86宗增长近4倍，其 ...

2026年开年，A股公司"南下"热潮持续涌动，多家公司向H股发起冲刺。 ◎记者 孔令仪 2026年开年这一波冲刺H股的A股公司，大多为科技企业。例如：聚辰股份是一家全球化的芯片设计高 新技术企业；景旺电子是全球领先的印制电路板及高端电子材料企业；鹏辉能源以科技创新驱动发展， 聚焦于电池产品及储能系统领域；德赛西威则是国际领先的移动出行科技公司之一，致力于实现智慧出 行的全球共享。 生物医药行业A股公司赴港上市意愿也颇为强烈。益方生物聚焦于肿瘤、自身免疫性疾病及代谢类疾病 等重大疾病领域，所有产品均为自主研发。资料显示，公司已成功推动两款创新药获批上市，并有三个 候选药物处于临床试验阶段。 据上海证券报记者初步梳理，2026年1月1日至1月8日，已有聚辰股份、鹏辉能源、正泰电器、德赛西 威、兴业银锡、华盛锂电等6家A股公司发布了筹划H股上市公告；景旺电子、益方生物、亿纬锂能、天 下秀等4家A股公司已向港交所递交招股书；先导智能申请发行H股并在港交所主板挂牌上市获得证监会 备案。 此外，道通科技于1月2日在港交所发布公告，新增海通国际证券为公司委任的整体协调人，澜起科技于 1月5日在港交所披露聆讯后资料集，距离" ...

Group 1 - The three major indices opened higher, with the CSI All Share Securities Company Index rising by 0.32%, and several securities firms, including Northeast Securities, Huatai Securities, and others, showing gains [1] - The Broker ETF (159842) increased by 0.45%, with a trading volume exceeding 15 million yuan and a premium rate of 0.03%, indicating active trading [1] - The Broker ETF has seen a net inflow of funds for three consecutive trading days, accumulating nearly 350 million yuan [1] Group 2 - Companies such as Hailan Home and Dalian Commercial have announced plans to submit listing applications to the Hong Kong Stock Exchange, contributing to a growing list of over 140 A-share companies planning to list or spin off subsidiaries in Hong Kong this year [2] - Chinese securities firms have captured over 60% of the market share in participating as sponsors for Hong Kong IPOs, establishing themselves as dominant players in this sector [2] - The new "National Nine Articles" policy aims to cultivate first-class investment banks, suggesting a long-term positive outlook for capital market activity, with recommendations to focus on opportunities in mergers and acquisitions, wealth management transformation, and large securities firms with strong capital [2]

Core Viewpoint - The trend of A-share companies listing in Hong Kong continues to rise, with 16 companies achieving "A+H" listings by November 24, and over 140 A-share companies proposing plans to list in Hong Kong or spin off subsidiaries [1] Group 1: Market Activity - As of November 24, 2025, 16 companies have completed "A+H" listings, and more than 140 A-share companies have plans for Hong Kong listings or subsidiary spin-offs [1] - The total IPO fundraising amount in Hong Kong has exceeded 200 billion HKD, making it the highest globally this year [1] Group 2: Strategic Implications - Companies view listing in Hong Kong as a strategic choice to broaden financing options and promote globalization [1] - The Hong Kong market is evolving from a "valuation lowland" to an international platform for Chinese assets [1] Group 3: Market Dynamics - Chinese securities firms hold over 60% of the IPO underwriting share in Hong Kong, creating a one-stop service chain for companies going abroad [1] - Recent policy measures, such as the addition of audit firm lists, are expected to facilitate further A-share companies' listings in Hong Kong [1] Group 4: Future Outlook - The number of A-share companies listing in Hong Kong is anticipated to remain high, with quality leading companies likely to see valuation recovery, while "pseudo-growth" companies may face stricter valuation scrutiny [1]

Market Performance - The pharmaceutical and biotechnology index declined by 1.66% from October 6 to October 10, underperforming the Shanghai Composite Index by 0.72 percentage points, marking three consecutive weeks of underperformance [1] - The innovative drug sector (BK1106) also fell by 1.09% during the same period, continuing its three-week downward trend [1] IPO Trends - A surge in IPO applications from innovative drug companies has been observed in Hong Kong, with notable companies like Betta Pharmaceuticals, Changchun High-tech, Baillie Gifford, and Borui Pharmaceuticals expected to achieve "A+H" listings [2] - The influx of A-share companies listing in Hong Kong is attributed to multiple factors, including policy support and improved market liquidity [2] - The Hong Kong Stock Exchange has relaxed public shareholding restrictions for "A+H" companies, which has created opportunities for A-share companies to list in Hong Kong [2] Clinical Trials - From October 6 to October 10, the National Medical Products Administration (NMPA) disclosed 85 clinical trial registration information, with 29 of these being new registrations for innovative drugs in Phase II or above [3] - Following the National Day and Mid-Autumn Festival holidays, the innovative drug sector experienced a significant downturn, with the Hong Kong innovative drug index dropping sharply [3] Business Development (BD) Trends - BD transactions have been a highlight for domestic innovative drugs this year, with total transaction amounts reaching $60.8 billion in the first half of the year, exceeding the total for the entire year of 2024 by $3.7 billion [3] - The market has shown a tendency for stock prices to decline following BD transactions, attributed to market expectations being overly optimistic [3] - The upcoming European Society for Medical Oncology (ESMO) annual meeting in Berlin will feature 23 research projects from China, indicating ongoing innovation in the sector [3] New Drug Approvals - The first IL-36R monoclonal antibody, HB0034, developed by Huazhong Tai Biological, has been submitted for market approval to treat adult generalized pustular psoriasis (GPP) [4] - GPP is a rare and potentially life-threatening skin disease, and currently, only one drug has been approved globally for its treatment [4] Industry Insights - The innovative drug sector is experiencing a return to a bubble-like state, with significant fluctuations in stock prices driven by BD news [4] - The founder of InnoCare Pharma expressed optimism about the industry's future, envisioning a time when Chinese companies will be recognized for their contributions to global health rather than just for their pipeline sales [4]

Core Viewpoint - The trend of A-share companies seeking to list in Hong Kong continues, with a significant number of companies announcing plans to do so in September 2023 [1] Group 1: A-share Companies Going Public in Hong Kong - As of September 30, three A-share listed companies, namely XinNuoWei, Kexing Pharmaceutical, and KOTAI Power, announced plans to list in Hong Kong [1] - In total, 25 A-share listed companies have announced plans to list in Hong Kong since the beginning of September 2023 [1] - As of October 2, there are 76 A-share listed companies that have submitted listing materials to the Hong Kong Stock Exchange and are awaiting hearings [1] Group 2: Industry Distribution - The A-share companies that have submitted applications for listing in Hong Kong cover various industries, including pharmaceuticals, telecommunications, food and beverages, automotive, and machinery [1] - Notable companies from multiple sectors are among those seeking to list in Hong Kong [1]

Core Viewpoint - Spring Airlines is considering an IPO in Hong Kong, potentially raising several hundred million USD, with discussions ongoing regarding the specifics of the issuance [1][2] Company Overview - Spring Airlines, listed on A-shares since 2015, is China's first privately listed airline, with a current market capitalization of 52.32 billion RMB as of September 30, 2025 [1] - The airline operates 134 aircraft and covers over 190 domestic routes and more than 50 international routes, focusing on popular tourist destinations in Asia [1] Financial Performance - For the first half of 2025, Spring Airlines reported revenue of 10.3 billion RMB, a year-on-year increase of 4.3%, while net profit decreased by 14% to 1.17 billion RMB [2] - The decline in net profit is attributed to the reduction of previously unrecognized deferred tax assets, impacting tax expenses significantly [2] - Excluding fluctuations in fuel and material costs, the airline's unit costs in July and August 2025 were lower than those in the same period of 2019 [2] Market Trends - There is a growing interest from investors in Chinese companies, leading to more firms considering listings on the Hong Kong Stock Exchange to support business expansion [2] - As of September 25, 2025, 11 A-share companies have successfully listed in Hong Kong, raising over 90 billion HKD, with more than 30 additional companies preparing for listings [3] Industry Context - The Hong Kong stock market has seen significant performance, with the Hang Seng Index and related indices showing year-to-date increases of 32.03%, 42.77%, and 29.55% respectively [3] - The trend of A-share companies seeking secondary listings in Hong Kong is driven by improved policies, increased internationalization needs, and enhanced liquidity in the Hong Kong market [3][5] Strategic Implications - If Spring Airlines successfully lists in Hong Kong, it would become another airline with dual listings (A+H), potentially setting a precedent for private airlines seeking financing [3] - The current environment is seen as a critical phase for Chinese companies "going global," with Hong Kong serving as a key hub for capital flow and international market access [5]

Group 1 - The core viewpoint of the article highlights the ongoing trend of A-share companies planning to list in Hong Kong, with 18 companies disclosing their intentions to do so in September 2023 [1] - Among these companies, Dongshan Precision announced on September 23 its plan to issue H-shares and list on the Hong Kong Stock Exchange [1] - The list of companies includes notable names such as Wufangzhai, Borui Pharmaceutical, and Haierland, indicating a broad interest across various sectors [1]

Core Viewpoint - The article discusses the recent announcement by the domestic clothing company HLA (海澜之家) to issue H-shares and list on the Hong Kong Stock Exchange, highlighting the trend of A-share companies seeking listings in Hong Kong due to policy support and international expansion strategies [2][6]. Company Overview - HLA, established in 1997, is a large retail group in China, covering self-owned brand operations, international brand licensing, and custom group purchases. The company has a diverse brand portfolio including men's, women's, children's, and professional clothing [4]. - The company went public in 2014 through a reverse merger with Kainuo Technology [4]. Strategic Intent of Hong Kong Listing - The primary goal of HLA's planned Hong Kong listing is to deepen its global strategic layout, accelerate overseas business development, and enhance its international brand image. The company aims to strengthen its capital base to support high-quality growth [4]. - HLA has been actively expanding internationally, with its first overseas store opened in Kuala Lumpur, Malaysia, in 2017. The company plans to further explore markets in Central Asia, the Middle East, and Africa, with a new store opening in Sydney, Australia, expected [4]. Financial Performance - In the first half of 2025, HLA reported revenue of 11.566 billion yuan, a year-on-year increase of 1.73%. However, the net profit attributable to shareholders decreased by 3.42% to 1.580 billion yuan. The company experienced a net reduction of 110 stores, bringing the total to 5,723, which is similar to levels from three years ago [5]. - The overseas market has shown promising growth, with 111 overseas stores generating 206 million yuan in revenue, a 27.42% increase compared to the same period last year [5]. Market Trends - The trend of A-share companies listing in Hong Kong has been gaining momentum, with 11 companies having done so by September 11, 2023. There are over 50 A-share companies currently in the queue for H-share listings [7]. - The Chinese regulatory environment has become more favorable for such listings, with the China Securities Regulatory Commission (CSRC) introducing measures to support leading enterprises in going public in Hong Kong [7]. Advantages of Hong Kong Listing - Hong Kong is viewed as a natural platform for companies aiming for global market development due to its international financial center status, legal framework, and tax advantages, such as a corporate tax rate of 16.5% [8]. - The Hong Kong Stock Exchange has implemented reforms to facilitate listings, including allowing dual-class shares and providing flexible financing options for innovative companies [8].

Core Viewpoint - The company, HLA (海澜之家), plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international presence [2][3]. Group 1: Company Strategy - HLA aims to deepen its global strategy and accelerate overseas business development through the upcoming Hong Kong listing [3][6]. - The company has been expanding internationally since 2017, with a focus on Southeast Asia and plans to open its first store in Australia [2][4]. - As of the first half of this year, HLA has 111 overseas stores, generating a revenue of 206 million yuan, a 27.42% increase year-on-year [4][5]. Group 2: Financial Performance - In the first half of the year, HLA reported a revenue of 11.566 billion yuan, a year-on-year increase of 1.73%, while net profit decreased by 3.42% to 1.580 billion yuan [3][4]. - The company's revenue fluctuated significantly from 2020 to 2024, with a notable decline in 2020 and a recovery in subsequent years, although 2024 showed a slight decrease [4][6]. Group 3: Market Context - The trend of A-share companies listing in Hong Kong is increasing, with 11 companies having done so this year, bringing the total to 161 A+H companies [2][7]. - The Hong Kong market is seen as a mature international financial center, providing a broader investor base and diverse financing channels for companies [6][7]. - Recent policy changes by the China Securities Regulatory Commission have facilitated the process for mainland companies to list in Hong Kong, further encouraging this trend [7].